基本情報
- CAS
76824-35-6- 標準SMILES
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1- InChIKey
XUFQPHANEAPEMJ-UHFFFAOYSA-N- 分子式
- C8H15N7O2S3
- 平均分子量
- 337.5 g/mol
- 単同位体質量
- 337.04493627
概要
Famotidine is a member of guanidines, a sulfonamide and a member of 1,3-thiazoles. It has a role as a H2-receptor antagonist, an anti-ulcer drug and a P450 inhibitor.
名称と識別子
- 優先名称
- Gastro
- IUPAC
- 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
- 現地名
- ファモチジン
- 英語名
- Famotidine
- 分子式
- C8H15N7O2S3
- 分子量
- 337.45
名称と別名
FamogardFamopsinFamovaneMensomaNevofamPurifamBrolinHacipGastroFamotidine-13C3ApogastineGastrodomina
名称をさらに表示
ファモチジンクリマーゲンODガノルストマルコンファモスタジンファモガスト-Dストマルコン-Dガスリック-D3-[[[2-[[アミノイミノメチル]アミノ]チアゾール-4-イル]メチル]チオ]-N2-(アミノスルホニル)プロパンアミジンペプデュルファノジルガモファー-DガステルホキサデュルファスタニールブロスターMガモファーケミガスチン3-[[[2-[(ジアミノメチレン)アミノ]-4-チアゾリル]メチル]チオ]-N2-(アミノスルホニル)プロパンイミドアミドガスイサンpepdinepepcidIfadaganormk208gastermotiaxmucloxpepdulpeptan
GastrosidinAntodineBestidineBlocacidConfobosCuantinDispronilFamocid
物性
構造計算による物性
- XLogP
- -0.6
- 極性表面積
- 238 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 8
- 回転可能結合数
- 7
- 重原子数
- 20
- 形式電荷
- 0
- 複雑度
- 469
実験および物理化学的性質
Drugs
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Gastric and Ulcer Drugs
Pharmaceuticals
LogP
-0.64
-0.56
Solubility1.0 mg/mL at 20 °C
Melting Point163.5 °C
Physical DescriptionSolid
Collision Cross Section
174.3 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID5023039]
171.05 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
167.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
165.9 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
物理化学的性質
- 融点
- 163 · 163-164°C
- 沸点
- 562.7 · 562.7±60.0 °C(Predicted)
- 比重(密度)
- 1.5111 · 1.5111 (rough estimate)
- 蒸気圧
- 1e-7 kPa · <0.0000001 kPa ( 25 °C)
- 屈折率
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
安全データ
- wgk
- 2
- rtecs
- UA2300000
- 毒性
- LD50 i.v. in mice: 244.4 mg/kg (Yasufumi)
- hs_code
- 29341000
- risk_code
- 20/21/22-45-61
- hazard_code
- T
- safety_code
- 22-24/25-53-45-36/37/39
- ストレージクラス
- 11 - Combustible Solids
- 有毒物質データの
- 76824-35-6(Hazardous Substances Data)
化学と産業
薬理情報
Protein BindingThe protein binding of famotidine is about 15 to 22%.
Pharmacodynamics
Famotidine decreases the production of gastric acid, suppresses acid concentration and pepsin content, and decreases the volume of gastric secretion. Famotidine inhibits both basal and nocturnal gastric acid secretion, as well as acid secretion stimulated by food, caffeine, insulin, and pentagastrin. Famotidine has a dose-dependent therapeutic action, with the highest dose having the most extended duration of action and the highest inhibitory effect on gastric acid secretion. Following oral administration, the onset of action is within one hour, and the peak effect is reached within 1-3 hours. The duration of effect is about 10-12 hours.
Mechanism of Action
Histamine acts as a local hormone that stimulates the acid output by parietal cells via a paracrine mechanism. Neuroendocrine cells called enterochromaffin-like (ECL) cells lie close to the parietal cells and regulate the basal secretion of histamine. Histamine release is also promoted from stimulation by acetylcholine and gastrin, a peptide hormone. Gastrin (G) cells release gastrin, which works on CCK<sub>2</sub> receptors on ECL cells. This action promotes the release of histamine from ECL cells. Upon release, histamine acts on H<sub>2</sub> receptors expressed on the basolateral membrane of parietal cells, leading to increased intracellular cAMP levels and activated proton pumps on parietal cells. Proton pump releases more protons into the stomach, thereby increasing the secretion of acid. In conditions that are associated with acid hypersecretion such as ulcers, there is a loss of regulation of acid secretion. Famotidine works on H<sub>2</sub> receptors and blocks the actions of histamine.
Biological Half-LifeThe elimination half-life is about 2 to 4 hours. The half-life is expected to increase nonlinearly in patients with decreased renal function.
Metabolism/MetabolitesFamotidine undergoes minimal first-pass metabolism. About 25-30% of the drug is eliminated through hepatic metabolism. The only metabolite identified in humans is the S-oxide.
関連反応
1 件
化合物ノート
読み込み中…